Evidence map›Paper›PMID 31197517›Full record

ArticleClinical & experimental metastasis2019

Hypermethylation-mediated inactivation of miR-124 predicts poor prognosis and promotes tumor growth at least partially through targeting EZH2/H3K27me3 in ESCC.

Ziqiang Tian, Zhenhua Li, Yonggang Zhu, Lingjiao Meng, Fei Liu, Meixiang Sang, Guiying Wang

Expression of concernAbstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ziqiang TianThoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Zhenhua LiThoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Yonggang ZhuThoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Lingjiao MengResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Fei LiuResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Meixiang SangResearch Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China.
Guiying WangThoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People's Republic of China. Tizq12@vip.163.com.
Hebei Medical University · CNFourth Hospital of Hebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidences indicated that some microRNAs (miRNAs) play a critical role during the carcinogenesis. In the present study, we found that miR-124 is down-regulated in esophageal squamous cell carcinoma (ESCC) tissues. Three miR-124 encoding genes, including mir-124-1, mir-124-2, and mir-124-3, harboring CpG islands undergo methylation-mediated miR-124 inactivation in ESCC tissues. The methylation status of all these three genes was negatively associated with the expression of miR-124. The low expression of miR-124 and the hypermethylation of mir-124-1 and mir-124-3 were associated with the clinico-pathological parameters indicating the poor prognosis. In addition, promoter methylation of all three genes plus low expression of miR-124 was the independent poor prognostic marker for ESCC patients. In conclusion, miR-124 may function as a tumor suppressive miRNA, and hypermethylation-mediated inactivation of miR-124 may be useful for a poor prognostic marker for ESCC patients.

Indexed as

DNA MethylationEnhancer of Zeste Homolog 2 ProteinEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaGenes, Tumor SuppressorHumansJumonji Domain-Containing Histone DemethylasesMicroRNAsPrognosisPromoter Regions, GeneticEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanJumonji Domain-Containing Histone DemethylasesMicroRNAsMIRN124 microRNA, humanEsophageal squamous cell carcinomaMethylationmiR-124mir-124-1mir-124-2mir-124-3

Identifiers

PMID31197517
OpenAlexW2951157641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.